• Delivra Health published its MD&A for the three and nine months ended March 31, 2026, reporting net revenue of CAD 1.25 million and CAD 6.89 million.
• Dream Water revenue fell to CAD 991,000 for the quarter, driven by reduced outbound shipments from the US to Middle East partners.
• Gross margin dropped to 25% from 50%, reflecting weaker volume, mix shifts, pricing, channel changes, higher e-commerce fees, third-party costs.
• Adjusted EBITDA swung to a loss of CAD 949,000 from a profit of CAD 124,000, while operating loss widened to CAD 978,000.
• Management expects shipment activity to resume in the fourth quarter, forecasting improved sales volumes, net revenue, adjusted EBITDA through fiscal 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delivra Health Brands Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.